HC Wainwright Brokers Boost Earnings Estimates for AQST

Aquestive Therapeutics, Inc. (NASDAQ:AQST) – Stock analysts at HC Wainwright upped their Q1 2026 earnings per share (EPS) estimates for shares of Aquestive Therapeutics in a research report issued to clients and investors on Monday, March 9th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of ($0.12) for the quarter, up from their prior estimate of ($0.13). The consensus estimate for Aquestive Therapeutics’ current full-year earnings is ($0.46) per share. HC Wainwright also issued estimates for Aquestive Therapeutics’ Q2 2026 earnings at ($0.11) EPS, Q3 2026 earnings at ($0.13) EPS, Q4 2026 earnings at ($0.15) EPS, FY2026 earnings at ($0.51) EPS, Q1 2027 earnings at ($0.15) EPS, Q2 2027 earnings at ($0.15) EPS, Q3 2027 earnings at ($0.12) EPS and Q4 2027 earnings at ($0.11) EPS.

AQST has been the subject of a number of other research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Aquestive Therapeutics in a research note on Wednesday, January 21st. Wall Street Zen raised shares of Aquestive Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, March 7th. Finally, Lake Street Capital set a $6.00 price objective on Aquestive Therapeutics in a research report on Tuesday, February 3rd. Two investment analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $8.80.

Aquestive Therapeutics Stock Performance

Aquestive Therapeutics stock opened at $4.27 on Wednesday. The firm has a market cap of $521.11 million, a PE ratio of -5.47 and a beta of 1.61. The firm’s 50 day moving average price is $4.08 and its two-hundred day moving average price is $5.21. Aquestive Therapeutics has a twelve month low of $2.12 and a twelve month high of $7.55.

Aquestive Therapeutics (NASDAQ:AQST) last posted its quarterly earnings results on Wednesday, March 4th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.13). The firm had revenue of $13.02 million for the quarter, compared to analyst estimates of $13.28 million.

Insider Activity

In other Aquestive Therapeutics news, COO Cassie Jung sold 45,791 shares of Aquestive Therapeutics stock in a transaction that occurred on Tuesday, March 10th. The shares were sold at an average price of $4.17, for a total value of $190,948.47. Following the completion of the sale, the chief operating officer directly owned 274,980 shares in the company, valued at $1,146,666.60. The trade was a 14.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO A Ernest Toth, Jr. sold 58,254 shares of the business’s stock in a transaction that occurred on Tuesday, March 10th. The stock was sold at an average price of $4.17, for a total transaction of $242,919.18. Following the completion of the sale, the chief financial officer directly owned 376,112 shares of the company’s stock, valued at $1,568,387.04. This represents a 13.41% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 395,690 shares of company stock valued at $1,650,027. 8.35% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Aquestive Therapeutics

Hedge funds have recently bought and sold shares of the business. Invesco Ltd. raised its holdings in Aquestive Therapeutics by 20.2% during the fourth quarter. Invesco Ltd. now owns 64,993 shares of the company’s stock valued at $420,000 after buying an additional 10,920 shares in the last quarter. Voloridge Investment Management LLC bought a new stake in shares of Aquestive Therapeutics during the 4th quarter worth about $1,254,000. Numerai GP LLC bought a new stake in shares of Aquestive Therapeutics during the 4th quarter worth about $789,000. Occudo Quantitative Strategies LP acquired a new position in shares of Aquestive Therapeutics during the 4th quarter valued at about $365,000. Finally, Millennium Management LLC increased its holdings in shares of Aquestive Therapeutics by 19.1% during the 4th quarter. Millennium Management LLC now owns 1,535,369 shares of the company’s stock valued at $9,918,000 after acquiring an additional 246,040 shares during the last quarter. 32.45% of the stock is owned by institutional investors and hedge funds.

More Aquestive Therapeutics News

Here are the key news stories impacting Aquestive Therapeutics this week:

• Positive Sentiment: HC Wainwright raised several near‑term EPS forecasts and lifted FY2026 estimates, signaling modestly improved analyst expectations for cash flow and operating performance. This supports a more constructive view on AQST’s outlook. HC Wainwright estimates (MarketBeat)
• Positive Sentiment: Sector writeups remain bullish on Anaphylm’s approval path and commercial potential; a Seeking Alpha piece keeps a Buy stance and models significant upside if packaging/labeling CRL issues are resolved and a pivotal PK study proceeds. That optimism supports investor appetite for the stock. Aquestive: Anaphylm closer to FDA approval (Seeking Alpha)
• Positive Sentiment: Major business press highlighted Aquestive among attractive healthcare names, adding broader visibility and possible momentum interest. Analysts bullish on healthcare stocks (Globe & Mail)
• Neutral Sentiment: Reported short‑interest data shows 0 shares and a 0.0 days‑to‑cover figure — likely a data artifact rather than a real change in short activity; treat as non‑informative until corrected. Short interest report (MarketBeat)
• Neutral Sentiment: Analyst models and commentary (Seeking Alpha) note Aquestive may need additional financing by end‑2027 to reach profitability — an important cash‑plan consideration but not an immediate catalyst. Financing note (Seeking Alpha)
• Negative Sentiment: Multiple law firms have filed or solicited investors to join securities‑class actions covering purchases from June 16, 2025 to Jan 8, 2026; potential litigation, lead‑plaintiff fights and related disclosures create legal risk and can pressure the stock. Deadline to seek lead plaintiff: May 4, 2026. Portnoy class action notice
• Negative Sentiment: Large insider sales were disclosed on March 10: CEO and several senior officers sold significant blocks at roughly $4.17 each, materially reducing reported insider stakes. Heavy insider selling often spooks investors even if sales are for diversification or pre‑arranged plans. CEO insider sale (SEC filing)

About Aquestive Therapeutics

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.